VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $53,523,545 | -18.5% | 1,049,893 | -20.2% | 17.09% | -7.2% |
Q2 2023 | $65,692,824 | +20.3% | 1,315,435 | -9.7% | 18.41% | -21.4% |
Q1 2023 | $54,619,604 | -21.8% | 1,457,300 | 0.0% | 23.40% | -20.3% |
Q4 2022 | $69,877,535 | +54.3% | 1,457,300 | -22.8% | 29.35% | +55.6% |
Q3 2022 | $45,299,000 | -44.9% | 1,887,478 | -50.0% | 18.86% | +10.6% |
Q2 2022 | $82,142,000 | +80.2% | 3,774,956 | +100.0% | 17.06% | +38.1% |
Q1 2022 | $45,582,000 | +1.5% | 1,887,478 | 0.0% | 12.35% | +9.9% |
Q4 2021 | $44,903,000 | -6.2% | 1,887,478 | 0.0% | 11.24% | +7.9% |
Q3 2021 | $47,885,000 | +12.7% | 1,887,478 | 0.0% | 10.42% | +36.8% |
Q2 2021 | $42,489,000 | +14.0% | 1,887,478 | 0.0% | 7.62% | -64.9% |
Q1 2021 | $37,277,000 | -25.7% | 1,887,478 | 0.0% | 21.71% | -25.5% |
Q4 2020 | $50,150,000 | -46.2% | 1,887,478 | 0.0% | 29.14% | -34.5% |
Q3 2020 | $93,203,000 | +56.2% | 1,887,478 | 0.0% | 44.51% | +21.4% |
Q2 2020 | $59,663,000 | – | 1,887,478 | – | 36.67% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |